Company:  IRONWOOD PHARMACEUTICALS ... (IRWD)
Form Type:  10-Q
Filing Date:  11/6/2012 
CIK:  0001446847 
Address:  301 BINNEY STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-621-7722 
Last Trade
Last Trade: 
$12.01  
Change: 
0.23 (1.95%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$1.40B
Description of Business
We are an entrepreneurial pharmaceutical company focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. If we do these things well, we hope to earn the right to continue doing them and, one step at a time, build an enduring pharmaceutical company that helps patients lead better lives. Our core strategy is to establish a leading gastrointestinal, or GI, therapeutics company, leveraging our development and commercial capabilities in addressing GI disorders as well as our pharmacologic expertise in guanylate cyclase, or GC, pathways. This expertise is based on our work advancing our lead product, linaclotide, which is the first, and to date, only product approved by the U.S. Food and Drug Administration, or FDA, in a new class of GI medicines called guanylate cyclase type-C, or GC-C, agonists.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures about ...
      Item 4. Controls and Procedures
    PART II - OTHER INFORMATION
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities
      Item 6. Exhibits
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATION PURSUANT
  EXHIBIT 31.2
    CERTIFICATION PURSUANT
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO
BROKERAGE PARTNERS